Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    PositiveID Corporation Signs Biodetector Agreement with NASA

    By Global Biodefense StaffMay 7, 2014
    NASA biological sciences research
    Share
    Facebook LinkedIn Reddit Email

    PositiveID Corporation announced this week that it has signed a Space Act Agreement with NASA’s Ames Research Center to collaborate on testing the company’s Firefly Dx detection system as a platform for biological research and commercial development for ground and space applications.

    The Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results using real-time TaqMan PCR (polymerase chain reaction) chemistry. Firefly Dx is intended to derive results from a sample in less than 20 minutes at the point of need, compared to two to four hours for a lab device.

    Under this Space Act Agreement, NASA will assess the company’s Firefly Dx technology for potential ground and space applications, while PositiveID will assess the technology to improve its development of the Firefly Dx hardware for extreme environments, such as Department of Defense field applications.

    William J. Caragol, Chairman and CEO of PositiveID, said, “We are very proud to collaborate with NASA’s world-class team of scientists and researchers on the continued development of Firefly to advance mission-critical applications for point-of-need diagnostics, both in space and on the front lines to protect our nation from future bioterrorism threats.”

    Source: PositiveID press release, adapted.

    Bioterrorism POC Diagnostics Ruggedized
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleNotable Contracts: Ricin Vaccine Award to GE Healthcare
    Next Article Black Death Shaped Mortality Patterns for Generations after Epidemic

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.